Gilead Sciences | Resultat Før Skat



Pre Tax Profit Lave om Dato
AbbVie USD 4.81B 1.54B 2024-12
Agios Pharmaceuticals USD -105399000 1.11B 2024-12
ALKERMES USD 443.75M 333.52M 2024-12
Alnylam Pharmaceuticals USD -193958000 85.3M 2024-12
Amgen USD 3.38B 111M 2024-12
Biogen USD 572.2M 118.5M 2024-12
BioMarin Pharmaceutical USD 169.64M 35.2M 2024-12
Bristol-Myers Squibb USD 4.26B 226M 2024-12
Eli Lilly USD 5.54B 3.83B 2024-12
Gilead Sciences USD 2.96B 112M 2024-12
GlaxoSmithKline GBP 563M 2.08B 2024-12
Glaxosmithkline USD 1.66B 1.78B 2024-12
Incyte USD 406.83M 147.12M 2024-12
J&J USD 5.42B 1.86B 2024-12
Merck USD 5.22B 114M 2024-12
Moderna USD -1184000000 1.2B 2024-12
Neurocrine Biosciences USD 162.6M 27.7M 2024-12
Novartis USD 4.66B 269M 2024-12
Pfizer USD 4.44B 2.36B 2024-12
PTC Therapeutics USD -97991000 12.26M 2024-09
Regeneron Pharmaceuticals USD 958.1M 534.9M 2024-12
Sanofi EUR 2.18B 1.33B 2024-12
Sarepta Therapeutics USD 171.74M 137.74M 2024-12
United Therapeutics USD 396.5M 7.9M 2024-12
Vertex Pharmaceuticals USD 1.32B 109.7M 2024-12



Gilead Sciences Resultat Før Skat - Aktuelle værdier, historiske data, prognoser, statistik, diagrammer og økonomisk kalender - Mar 2025.